Evolus Joins Nasdaq Biotechnology Index
Evolus, Inc. (NASDAQ: EOLS) has been added to the Nasdaq Biotechnology Index (NBI) as part of its annual reconstitution. This inclusion is expected to enhance Evolus' visibility and shareholder base. CFO Lauren Silvernail indicated that robust sales and market share gains position the company for a strong finish in 2021 and growth in 2022. Evolus focuses on innovative aesthetic products, particularly Jeuveau®, a neurotoxin exclusively for aesthetics, approved in 2019 by the FDA.
- Inclusion in Nasdaq Biotechnology Index may enhance visibility and attract more investors.
- Strong sales and market share gains reported, indicating positive business performance.
- Potential risks related to compliance with settlement agreements could impact future performance.
- Uncertainties regarding market adoption of Jeuveau® and competition may hinder growth.
- Company Anticipates Strong Finish to 2021
“We are pleased to be added to the NBI, which should enable us to expand our shareholder base and continue to help elevate our capital markets profile,” said
About
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words “plans,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company’s forward-looking statements include, but are not limited to, statements made by
Forward-looking statements involve risks and uncertainties that could cause actual results or experiences to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Jeuveau®, the efficiency and operability of our digital platform, competition and market dynamics, and our ability to maintain regulatory approval of Jeuveau® and other risks described in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended
Jeuveau® is a registered trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005262/en/
Investor/Media Contact:
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Source:
FAQ
What does the inclusion of Evolus (EOLS) in the Nasdaq Biotechnology Index mean?
What are the recent sales trends for Evolus (EOLS)?
Are there any risks associated with Evolus (EOLS)?